Loading...
Market
Expansion of Cancer Targets for HRO761 by End of 2025
5
Resolution / Starting Odds
0 • 25%
1 • 25%
2 • 25%
3 or more • 25%
Research publications or official announcements from NIBR or Vividion
Story
Breakthrough WRN Inhibitor HRO761 Targets MSI Cancers, Poised for Clinical Trials
Apr 24, 2024, 07:56 PM
Recent research has led to the discovery of a novel inhibitor, HRO761, targeting Werner Helicase (WRN), which shows synthetic lethality in microsatellite instability (MSI) cancers. This breakthrough, published in Nature, was achieved through chemoproteomic techniques that identified a covalent allosteric inhibitor of WRN. The research, spearheaded by NIBR and involving Vividion, marks a significant advancement in cancer treatment, particularly by transforming an ATP-competitive compound into an ATP-cooperative analogue. The development is poised for clinical testing to evaluate its effectiveness in human models of disease.
View original story
Similar markets
None • 25%
One • 25%
Two • 25%
Three or more • 25%
Remains focused solely on liver diseases • 33%
Expands to include other organ-specific diseases • 33%
Expands to include systemic diseases • 33%
Breast Cancer • 25%
Lung Cancer • 25%
Prostate Cancer • 25%
Colorectal Cancer • 25%
Yes • 50%
No • 50%
More than 3 • 25%
3 • 25%
2 • 25%
1 or none • 25%
Phase 4 trial • 25%
Approval in additional markets • 25%
Development of new formulations • 25%
Strategic partnership or collaboration • 25%
0-5 • 25%
6-10 • 25%
11-20 • 25%
More than 20 • 25%
Lung Cancer • 25%
Breast Cancer • 25%
Prostate Cancer • 25%
Colon Cancer • 25%